ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Charlotte, NC, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Charlotte, North Carolina, United States and 59 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Charlotte, North Carolina, United States and 122 other locations

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

"study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: BNT116

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Charlotte, North Carolina, United States and 56 other locations

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non...

Active, not recruiting
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Drug: Erlotinib 150/100 mg
Drug: AZD9291 80 mg/40 mg + placebo

Phase 3

AstraZeneca
AstraZeneca

Salisbury, North Carolina, United States and 169 other locations

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) ca...

Enrolling
Non-Small Cell Lung Cancer
EGFR/HER2 Exon 20 Insertion Mutation
Drug: STX-721 (3 dose levels)
Drug: STX-721 (Escalated)

Phase 1, Phase 2

Antares Therapeutics, Inc

Charlotte, North Carolina, United States and 19 other locations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. ...

Enrolling
Lung Cancer, Non-squamous, Non-small Cell
Drug: carboplatin
Drug: pemetrexed

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Rock Hill, South Carolina, United States and 168 other locations

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

(SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Biological: Sacituzumab Govitecan-hziy (SG)
Drug: Docetaxel

Phase 3

Gilead Sciences
Gilead Sciences

Charlotte, North Carolina, United States and 226 other locations

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and...

Active, not recruiting
Non Small Cell Lung Cancer
Lung Cancer Stage III
Drug: Paclitaxel
Drug: Durvalumab

Phase 2

Wake Forest University (WFU)
Wake Forest University (WFU)

Charlotte, North Carolina, United States

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)

as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) wh...

Active, not recruiting
Lung Cancer, Non-Small Cell
Biological: Pembrolizumab
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Charlotte, North Carolina, United States and 188 other locations

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: TAK-788

Phase 1, Phase 2

Takeda
Takeda

Charlotte, North Carolina, United States and 61 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems